This page is the primary source of information for your migration steps and resources. Always start with this page to contact us with questions, find dates and take action on confirming your status.
GT Biopharma, Inc. announced the successful completion of Cohort 1 in its Phase 1 trial for GTB-3650, a treatment for relapsed or refractory CD33 expressing hematologic malignancies. Following a ...
- Proof-of-activity now established for PBGENE-HBV, the first and only clinical modality designed to eliminate covalently closed circular DNA (cccDNA) and inactivate integrated DNA, with the goal of ...
Precision BioSciences (NASDAQ:DTIL) added ~6% in the premarket on Wednesday after the gene therapy developer announced initial safety and efficacy data from an early-stage trial for its Hepatitis B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results